Therapy Areas: Cardiovascular
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
20 October 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Monday announced new results from the FLUNITY-HD study, published in The Lancet, confirming that its high-d...
Avacta reports promising Phase 1a data for faridoxorubicin at ESMO 2025
20 October 2025 - Life sciences company Avacta Group PLC (AIM: AVCT) announced on Monday that it presented new Phase 1a data for its lead programme, faridoxorubicin (FAP-Dox, AVA6000), at the 2025 Eur...
Jacobio Pharma partners with Oceanpine Capital to focus on core oncology pipeline
16 October 2025 - Chinese pharmaceutical company Jacobio Pharma (HK:1167) announced on Wednesday that its subsidiary Beijing Jacobio Pharmaceuticals Co Ltd has entered into a Capital Increase and Equi...
Johnson & Johnson to separate its Orthopaedics business as standalone DePuy Synthes
14 October 2025 - Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) on Tuesday announced plans to separate its Orthopaedics business, creating an independent company that will ope...
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
13 October 2025 - Hong Kong-based Ascletis Pharma Inc (HKEX: 1672) has selected ASC35, a once-monthly, potentially best-in-class subcutaneously (SQ) administered GLP-1 receptor (GLP-1R)/GIP receptor (...
Lundbeck's bexicaserin granted Breakthrough Therapy Designation in China to treat seizures in severe rare epilepsies
13 October 2025 - Danish pharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) announced on Monday that its investigational drug bexicaserin, for the treatment of seizures associated with Developmental ...